Form 4: Chimerix SVP Michael Alrutz Reports Share and Option Cancellation Following Merger with Jazz Pharmaceuticals
SEC Form 4 Filing
Michael Alrutz, SVP and General Counsel of Chimerix, reports the cancellation of shares and stock options following the merger with Jazz Pharmaceuticals, as detailed in a Form 4 filing.
Summary
- Michael Alrutz, SVP and General Counsel of Chimerix, filed a Form 4 detailing changes in beneficial ownership.
- The filing reports transactions related to the merger between Chimerix and Jazz Pharmaceuticals, which became effective on April 21, 2025.
- As part of the merger agreement, Chimerix common stock was acquired for $8.55 per share.
- Outstanding restricted stock units (RSUs) were cancelled and converted into the right to receive a cash payment based on the offer price.
- In-the-money stock options were accelerated, vested, and converted into the right to receive a cash payment equal to the difference between the offer price and the exercise price.
- Out-of-the-money stock options were cancelled with no consideration.
Sentiment
Score: 6
Explanation: Neutral sentiment as the document primarily reports the execution of a previously announced merger agreement. While some individuals may have lost unvested or out-of-the-money options, the overall tone is factual and descriptive.
Positives
- Holders of in-the-money stock options received a cash payment representing the difference between the offer price and the exercise price.
- Holders of restricted stock units received a cash payment based on the offer price.
Negatives
- Holders of out-of-the-money stock options did not receive any consideration as their options were cancelled.
- Shareholders no longer own shares in Chimerix as the company is now a wholly owned subsidiary of Jazz Pharmaceuticals.
Future Outlook
The document does not contain specific forward-looking statements beyond the completion of the merger.
Management Comments
- The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
- In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.
Industry Context
This announcement reflects a continuation of M&A activity in the pharmaceutical industry, where larger companies acquire smaller firms to expand their product portfolios and pipelines.
Comparison to Industry Standards
- Merger and acquisition (M&A) transactions in the pharmaceutical industry often involve similar terms regarding the treatment of outstanding equity awards.
- The cancellation of out-of-the-money options and the cash-out of in-the-money options are standard practices in M&A deals.
- Comparable companies like Seattle Genetics (acquired by Pfizer) and Biohaven (acquired by Pfizer) also saw similar treatment of equity awards during their respective acquisitions.
Stakeholder Impact
- Shareholders received $8.55 per share in cash.
- Employees holding in-the-money options received a cash payment.
- Employees holding out-of-the-money options did not receive any consideration.
- Chimerix now operates as a wholly owned subsidiary of Jazz Pharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| March 4, 2025 | Date of the Agreement and Plan of Merger between Chimerix, Jazz Pharmaceuticals, and Pinetree Acquisition Sub, Inc. |
| March 10, 2025 | Date of 3,093 shares acquired under the Issuer's Employee Stock Purchase Plan. |
| April 17, 2025 | Expiration date of the tender offer for all outstanding shares of Chimerix common stock. |
| April 21, 2025 | Effective date of the merger between Purchaser and Chimerix. |
| January 8, 2026 | Expiration date of some employee stock options. |
| August 1, 2025 | Expiration date of some employee stock options. |
| January 24, 2027 | Expiration date of some employee stock options. |
| January 25, 2028 | Expiration date of some employee stock options. |
| January 23, 2029 | Expiration date of some employee stock options. |
| January 21, 2030 | Expiration date of some employee stock options. |
| January 22, 2031 | Expiration date of some employee stock options. |
| January 18, 2032 | Expiration date of some employee stock options. |
| January 16, 2033 | Expiration date of some employee stock options. |
| January 31, 2034 | Expiration date of some employee stock options. |
| January 6, 2035 | Expiration date of some employee stock options. |
Keywords
Merger Agreement, Chimerix, Jazz Pharmaceuticals, Form 4, Beneficial Ownership, Stock Options, RSUs, Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.